Vista Pharmaceuticals posts fifth straight loss as cash dwindles
Revenue halved to ₹539.95 lakhs while the auditor flagged material uncertainty over the company's survival.
What's new
- Net loss of ₹1,206.12 lakhs marks the fifth consecutive year of losses.
- Revenue fell to ₹539.95 lakhs from ₹1,007.46 lakhs in the prior year.
- Auditor flagged material uncertainty regarding the company's ability to continue as a going concern.
Why this matters
The company is in a liquidity trap with only ₹10.70 lakhs in cash and negative working capital of ₹13,186 lakhs. Management is pinning its survival on warrant subscription proceeds, but the persistent defaults on statutory dues like TDS and PF make that recovery path look thin.
What we're watching
- Whether the ₹922.50 lakhs in warrant proceeds actually materialize.
- Further auditor qualifications regarding the company's going concern status.
- Any legal action from creditors following the reported loan defaults.
The full read
Vista Pharmaceuticals is running out of road. For the fifth year in a row, the company reported a loss, this time totaling ₹1,206.12 lakhs. Revenue has cratered to ₹539.95 lakhs, down from ₹1,007.46 lakhs just a year ago. The balance sheet is equally strained, with negative working capital of ₹13,186 lakhs and only ₹10.70 lakhs in cash on hand. The company has already written off ₹821.74 lakhs in bad debt and is currently defaulting on statutory obligations, including TDS and PF contributions. The auditor has formally flagged a material uncertainty regarding the company's ability to continue as a going concern. Management is betting on ₹922.50 lakhs from warrant subscriptions to bridge the gap. That is the only remaining lifeline. For a company with a market cap of ₹49 crore, the margin for error is gone.
Questions answered
- How severe is the company's liquidity crisis?
- The company holds only ₹10.70 lakhs in cash against a negative working capital position of ₹13,186 lakhs. It has also defaulted on loan repayments and statutory dues, including TDS and PF contributions.
- What is the auditor's stance on the company's future?
- The auditor has issued a warning regarding material uncertainty over the company's ability to continue as a going concern. This is due to the combination of persistent losses and a lack of liquid assets.
- What caused the sharp drop in revenue?
- Revenue fell to ₹539.95 lakhs for the year ended March 31, 2026, compared to ₹1,007.46 lakhs in the previous year. The company also wrote off ₹821.74 lakhs in trade receivables that it deemed uncollectible.
- How does management plan to address the cash shortage?
- Management expects to receive ₹922.50 lakhs from outstanding warrant subscription proceeds to improve liquidity. They are also relying on continued promoter support to maintain operations.